Page 51 - AN-4-4

Advanced Neurology Lipid metabolism and Parkinson’s disease

doi: 10.1146/annurev.bi.64.070195.001531 The role of ceramide and sphingosine-1-phosphate in
Alzheimer’s disease and other neurodegenerative disorders.
95. Wang K, Xu H, Zou R, et al. PCYT1A deficiency disturbs
fatty acid metabolism and induces ferroptosis in the mouse Mol Neurobiol. 2019;56(8):5436-5455.
retina. BMC Biol. 2024;22(1):134. doi: 10.1007/s12035-018-1448-3
doi: 10.1186/s12915-024-01932-y 106. Abbott SK, Li H, Muñoz SS, et al. Altered ceramide acyl
96. Wood PL, Tippireddy S, Feriante J, Woltjer RL. Augmented chain length and ceramide synthase gene expression in
frontal cortex diacylglycerol levels in Parkinson’s disease Parkinson’s disease. Mov Disord. 2014;29(4):518-526.
and lewy body disease. PLoS One. 2018;13(3):e0191815. doi: 10.1002/mds.25729
doi: 10.1371/journal.pone.0191815 107. Vos M, Dulovic-Mahlow M, Mandik F, et al. Ceramide
97. Stoessel D, Schulte C, Teixeira Dos Santos MC, et al. accumulation induces mitophagy and impairs β-oxidation
Promising metabolite profiles in the plasma and CSF of in PINK1 deficiency. Proc Natl Acad Sci U S A.
early clinical Parkinson’s disease. Front Aging Neurosci. 2021;118(43):e2025347118.
2018;10:51. doi: 10.1073/pnas.2025347118
doi: 10.3389/fnagi.2018.00051 108. Lim JR, Chae CW, Park JY, et al. Ethanol-induced ceramide
98. Farmer K, Smith CA, Hayley S, Smith J. Major alterations of production causes neuronal apoptosis by increasing MCL-
phosphatidylcholine and lysophosphotidylcholine lipids in 1S-mediated ER-mitochondria contacts. Neurobiol Dis.
the substantia nigra using an early stage model of Parkinson’s 2023;177:106009.
disease. Int J Mol Sci. 2015;16(8):18865-18877. doi: 10.1016/j.nbd.2023.106009
doi: 10.3390/ijms160818865 109. Motyl J, Przykaza Ł, Boguszewski PM, Kosson P,
99. Shahmoradian SH, Lewis AJ, Genoud C, et al. Lewy pathology Strosznajder JB. Pramipexole and fingolimod exert
in Parkinson’s disease consists of crowded organelles and neuroprotection in a mouse model of Parkinson’s disease
lipid membranes. Nat Neurosci. 2019;22(7):1099-1109. by activation of sphingosine kinase 1 and Akt kinase.
Neuropharmacology. 2018;135:139-150.
doi: 10.1038/s41593-019-0423-2
doi: 10.1016/j.neuropharm.2018.02.023
100. Farid I, Ali A, Holman AP, Osborne L, Kurouski D. Length
and saturation of choline plasmalogens alter the aggregation 110. Wang R, Sun H, Cao Y, et al. Glucosylceramide
rate of α-synuclein but not the toxicity of amyloid fibrils. Int accumulation in microglia triggers STING-dependent
J Biol Macromol. 2024;264(Pt 1):130632. neuroinflammation and neurodegeneration in mice. Sci
Signal. 2024;17(829):eadk8249.
doi: 10.1016/j.ijbiomac.2024.130632
doi: 10.1126/scisignal.adk8249
101. O’Leary EI, Jiang Z, Strub MP, Lee JC. Effects of
phosphatidylcholine membrane fluidity on the conformation 111. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease
and aggregation of N-terminally acetylated α-synuclein. glucocerebrosidase and α-synuclein form a bidirectional
J Biol Chem. 2018;293(28):11195-11205. pathogenic loop in synucleinopathies. Cell. 2011;146(1):37-52.
doi: 10.1074/jbc.RA118.002780 doi: 10.1016/j.cell.2011.06.001
102. Mu J, Lam SM, Shui G. Emerging roles and therapeutic 112. Seo BA, Kim D, Hwang H, et al. TRIP12 ubiquitination of
potentials of sphingolipids in pathophysiology: Emphasis on glucocerebrosidase contributes to neurodegeneration in
fatty acyl heterogeneity. J Genet Genomics. 2024;51(3):268-278. Parkinson’s disease. Neuron. 2021;109(23):3758-3774.e11.
doi: 10.1016/j.jgg.2023.06.006 doi: 10.1016/j.neuron.2021.09.031
103. Gomez-Larrauri A, Presa N, Dominguez-Herrera A, 113. Belarbi K, Cuvelier E, Bonte MA, et al. Glycosphingolipids
Ouro A, Trueba M, Gomez-Muñoz A. Role of bioactive and neuroinflammation in Parkinson’s disease. Mol
sphingolipids in physiology and pathology. Essays Biochem. Neurodegener. 2020;15(1):59.
2020;64(3):579-589. doi: 10.1186/s13024-020-00408-1
doi: 10.1042/EBC20190091 114. Boland S, Swarup S, Ambaw YA, et al. Deficiency of the
104. Bras J, Singleton A, Cookson MR, Hardy J. Emerging frontotemporal dementia gene GRN results in gangliosidosis.
pathways in genetic Parkinson’s disease: Potential role Nature Commun. 2022;13(1):5924.
of ceramide metabolism in lewy body disease. FEBS J. doi: 10.1038/s41467-022-33500-9
2008;275(23):5767-5773.
115. Maglione V, Marchi P, Di Pardo A, et al. Impaired ganglioside
doi: 10.1111/j.1742-4658.2008.06709.x
metabolism in Huntington’s disease and neuroprotective
105. Czubowicz K, Jęśko H, Wencel P, Lukiw WJ, Strosznajder RP. role of GM1. J Neurosci. 2010;30(11):4072-4080.

Volume 4 Issue 4 (2025) 45 doi: 10.36922/AN025320086